Inventor

HANNA NABIL

US50 patents

⚠️ This page may combine multiple inventors who share the name “HANNA NABIL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

HANNA NABIL

BIOGEN IDEC INC

Anti-CD20 antibodies

Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma

Expression and use of anti-CD20 antibodies

Production of tetravalent antibodies

Recombinant anti-CD4 antibodies for human therapy

CD80 specific antibodies

Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4

Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4

Expression and use of anti-CD20 Antibodies

TAG-72 specific CH2 domain deleted antibodies

Method for preparing anti-MIF antibodies

Treating allergic diseases with humanized anti-CD40L antibody

Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis

Treating autoimmune diseases with humanized anti-CD40L antibody

Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies

Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Host cells expressing 7C10 and 16C10 CD80-specific antibodies

7C10 and 16C10 CD80-specific antibodies

Anti-CD80 antibodies

Recombinant anti-CD4 antibodies for human therapy

Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies

Methods of producing 7C10 and 16C10 CD80-specific antibodies

Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies

IDEC PHARMA CORP

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma

Humanized antibodies to human gp39, compositions containing thereof

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Recombinant antibodies for human therapy

Recombinant antibodies for human therapy

Recombinant antibodies for human therapy

Recombinant antibodies for human therapy

Recombinant antibodies for human therapy

Recombinant anti-CD4 antibodies for human therapy

Methods of treating autoimmune diseases with gp39-specific antibodies

Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies

SMITHKLINE BECKMAN CORP

Inhibition of 5-lipoxygenase products

Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor

Inhibition of interleukin-1 production by monocytes and/or macrophages

Inhibition of interleukin-1 by monocytes and/or macrophages

Inhibition of interleukin-1 production by monocytes and/or macrophages

Inhibition of the 5-lipoxygenase pathway

SMITHKLINE BEECHAM CORP

Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages

Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors

Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors

Inhibition of the 5-lipoxygenase pathway

(unassigned)

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Methods for treating b cell lymphoma using CD80-specific antibodies

Treatment of psoriasis using anti-B7.1 (CD80) antibodies